Nonpres (Eplerenone)

Eplerenone selectively blocks aldosterone at the mineralocorticoid receptor, preventing sodium and water retention while conserving potassium. This results in decreased blood volume, lower blood pressure, and reduced strain on the heart.

The specific dose of Nonpres is determined by the prescribing clinician based on the individual’s medical condition, renal function, and potassium levels. Dosage adjustments are made according to therapeutic response and safety monitoring.

Eplerenone is classified as Pregnancy Category B, indicating that animal studies have not shown risk, but there are limited human data. It should be used only if the potential benefit outweighs any possible risk, and breastfeeding decisions should be made with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Eplerenone belongs to the mineralocorticoid receptor antagonist class, differing from ACE inhibitors, ARBs, beta‑blockers, and calcium‑channel blockers. It offers a targeted mechanism that reduces potassium loss, but requires careful monitoring of serum potassium and renal function, unlike some other antihypertensives.

Nonpres should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s stability and potency throughout its shelf life.

Nonpres is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include severe hyperkalaemia, which can cause cardiac arrhythmias, and acute renal impairment. Patients should be monitored regularly for serum potassium and kidney function, especially when initiating therapy or adjusting doses.

Nonpres is contraindicated in patients with severe renal impairment, hyperkalaemia, or known hypersensitivity to eplerenone or other mineralocorticoid receptor antagonists. It should also be avoided in individuals taking concurrent potassium‑sparing agents without close monitoring.